Recommended Dosages for Farxiga (Dapagliflozin) and Glipizide
For dapagliflozin (Farxiga): start with 5 mg once daily for glycemic control, which can be increased to 10 mg once daily if additional glucose lowering is needed; for cardiovascular and kidney protection indications, use 10 mg once daily. 1
For glipizide: initiate conservatively at 2.5 mg once daily and titrate slowly to avoid hypoglycemia, particularly in patients with reduced kidney function. 2
Dapagliflozin (Farxiga) Dosing
For Glycemic Control in Type 2 Diabetes
- Starting dose: 5 mg orally once daily 1
- Maximum dose: 10 mg orally once daily if additional glycemic control is needed 1
- Timing: Can be taken at any time of day, with or without food
For Cardiovascular and Kidney Protection
- Standard dose: 10 mg orally once daily for all non-glycemic indications 1
- This includes:
- Reducing risk of sustained eGFR decline, ESKD, CV death, and heart failure hospitalization in chronic kidney disease
- Reducing risk of CV death, heart failure hospitalization, and urgent heart failure visits in heart failure patients
- Reducing risk of heart failure hospitalization in T2DM patients with established CVD
Kidney Function Adjustments
For glycemic control:
- eGFR ≥45 mL/min/1.73 m²: No dose adjustment needed 3, 2, 1
- eGFR <45 mL/min/1.73 m²: Not recommended for glycemic control (ineffective due to mechanism of action) 3, 2, 1
For cardiovascular/kidney protection indications:
- eGFR ≥25 mL/min/1.73 m²: Use standard 10 mg dose 2, 1
- eGFR <25 mL/min/1.73 m²: Do not initiate, but may continue 10 mg if already on therapy 2, 1
- eGFR <20 mL/min/1.73 m²: Initiation not recommended, but continuation acceptable for kidney/CV benefit until dialysis 2
Important Considerations
- Withhold for at least 3 days before major surgery or prolonged fasting to reduce ketoacidosis risk 1
- The glucose-lowering effect diminishes as eGFR declines, but cardiovascular and kidney benefits persist 2
Glipizide Dosing
Standard Dosing
- Initial dose: 2.5 mg once daily (conservative initiation) 2
- Titration: Increase slowly based on glycemic response and tolerability
- Timing: Typically taken before meals
Kidney Function Adjustments
- All stages of CKD (eGFR 30-44 mL/min/1.73 m²): Initiate conservatively at 2.5 mg once daily and titrate slowly to avoid hypoglycemia 2
- Severe kidney impairment: Use with extreme caution due to increased hypoglycemia risk
- Note: Glyburide (not glipizide) is specifically not recommended in kidney disease 2
Critical Clinical Pitfalls
For Dapagliflozin
- Volume depletion risk: Assess volume status before initiation; consider reducing diuretic doses in at-risk patients 2
- Genital mycotic infections: Occur in ~6% of patients (vs. 1% placebo); counsel on hygiene 2
- Ketoacidosis risk: Rare but serious; maintain at least low-dose insulin in insulin-requiring patients; implement sick-day protocols 2
- Reversible eGFR decline: Expected initial drop of 3-5 mL/min/1.73 m² is hemodynamic and not a reason to discontinue 2
For Glipizide
- Hypoglycemia: Major concern, especially in elderly and those with kidney disease; occurs in ~40-46% of patients in comparative trials 4, 5
- Weight gain: Average 1.2 kg gain vs. 3.2 kg loss with dapagliflozin 5
- Poor glycemic durability: Coefficient of failure 0.59%/year vs. 0.13%/year with dapagliflozin 4
Combination Considerations
When adding dapagliflozin to patients already on glipizide, reduce or discontinue the sulfonylurea to prevent hypoglycemia, as dapagliflozin provides glucose lowering without insulin stimulation 6.